Chronic kidney disease in type 2 diabetes patients with metabolic associated steatotic liver disease

Yesmine Elloumi; Mouna Elleuch; Maryem Akacha; Khouloud Boujelben; Hadjkacem Faten; Nadia Charfi; Mouna Mnif; Salah Dhoha Ben; Majdoub Nabila Rekik

doi:10.1530/endoabs.110.EP545

EP545

Prev Next

Section Contents Cite

Endocrine Abstracts (2025) 110 EP545 | DOI: 10.1530/endoabs.110.EP545

ECEESPE2025 ePoster Presentations Diabetes and Insulin (245 abstracts)

Chronic kidney disease in type 2 diabetes patients with metabolic associated steatotic liver disease

Yesmine Elloumi ¹ , Mouna Elleuch ¹ , Maryem Akacha ¹ , Khouloud Boujelben ¹ , Hadjkacem Faten ¹ , Nadia Charfi ¹ , Mouna Mnif ¹ , Dhoha Ben Salah ¹ & Nabila Rekik Majdoub ¹

Author affiliations

¹Hedi Chaker University Hospital, Endocrinology Department, Sfax, Tunisia

JOINT466

Background: Chronic kidney disease (CKD) is a common complication in type 2 diabetes mellitus (T2DM) patients, and its clinical profile may be altered by the presence of Metabolic Associated Steatotic Liver Disease (MASLD). While the association between these two conditions is increasingly recognized, their combined impact on renal function requires further investigation. This study aims to describe the CKD profile in T2DM patients with MASLD.

Methods: This retrospective descriptive study included T2DM patients with confirmed MASLD, followed from 2012 to 2024 at the Endocrinology-Diabetology Department of Hedi Chaker University Hospital in Sfax, Tunisia. The study focused on CKD, analyzing its stages based on glomerular filtration rate (GFR) and levels of albuminuria. Albuminuria was classified as mild (<30 mg/g of urinary creatinine), microalbuminuria (30–300 mg/g of urinary creatinine), and macroalbuminuria (proteinuria) defined as values exceeding these thresholds.

Results: We included 101 patients in this study. The mean age of patients was 53.7 (±15.2) years, with a female predominance of 62.4%. CKD-G1, defined by a GFR of ≥90 ml/min/1.73m², was observed in 43.6% of patients. In comparison, CKD-G2, characterized by a GFR ranging from 60 to 89 ml/min/1.73m², was found in 28.7% of the cases. Furthermore, CKD-G3, with a GFR between 30 and 59 ml/min/1.73m², was present in 10.9%, while CKD-G4, where the GFR ranged from 15 to 29 ml/min/1.73m², was identified in 15.8% of patients. Notably, CKD-G5, indicating a severe reduction in renal function with a GFR <15 ml/min/1.73m², was seen in only 1%. Regarding albuminuria, a normal to mildly elevated level was detected in 56.4% of patients, whereas microalbuminuria was observed in 35.6%, and proteinuria was found in 7.9%.

Conclusion: These findings collectively highlight the diverse renal involvement in this population, underscoring the need for vigilant monitoring and early therapeutic interventions.